Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSO-021 + paclitaxel
- Development stage
- Phase 2
- Lead developer
- RS Oncology
- Modality
- Small Molecules
- Administration
- Intrapleural, Intravenous
01
Overview
RSO-021 + paclitaxel is an investigational **combination therapy** for the treatment of malignant pleural effusion (MPE) in patients with advanced solid tumors, including mesothelioma, breast, ovarian, and non-small cell lung cancers. RSO-021 is a novel small molecule inhibitor of mitochondrial peroxiredoxin 3 (PRX3) that acts by covalently inactivating PRX3, leading to increased oxidative stress and selective tumor cell death. Paclitaxel is a widely used chemotherapeutic that stabilizes microtubules, thereby inhibiting cell division and inducing apoptosis. In clinical trials, RSO-021 is administered weekly via intrapleural infusion, while paclitaxel is administered systemically, in accordance with standard of care. The combination aims to enhance anti-tumor effects via complementary mechanisms: RSO-021 disrupts cellular redox balance specifically within mitochondria of cancer cells, while paclitaxel disrupts cell division[1][2][3][5][7][9]. The combination is currently being evaluated in phase 2 clinical studies for efficacy and safety in patients with MPE due to advanced metastatic solid tumors.
- Brand names
- TaxolAbraxaneOnxolNaveruclifPazenir
- Other names
- RSO-021 + paclitaxel
02
Targets
PRDX3 (Peroxiredoxin-3)TUBB (Tubulin (alpha and beta subunits))BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on RSO-021 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSO-021 + paclitaxel.